Coming soon in March 2026, an IMMUNO-model event entitled: MODELS, CHALLENGES AND PROMISES OF ADVANCED THERAPIES FOR CANCER: NK CELLS IN THE CLINIC AND INDUSTRY
The event will be held at the Spanish National Centre for Biotechnology (CNB-CSIC) in Madrid, March 5-6, 2026 and will bring together researchers, clinicians and industry experts, offering a unique platform to share recent efforts in innovation on advanced therapies.
The scientific sessions will include keynote talks by international scientists and clinicians, experts in the transfer of new therapies to the clinic and industry. As a novelty, we will have several roundtables in which invited specialists will discuss other crucial aspects to consider when planning translational research such as regulatory issues, how to work in a clean room and business aspects. Talks and roundtables will include these topics:
Talks by experts: Tumour recognition by NK cells, NK cell enhancer biomolecules, Successful NK cell-based therapies in the clinics
Roundtable 1: Regulatory aspects: how to understand guidelines for experimental design, how to reach regulatory agencies
Roundtable 2: The clean room and therapeutics production
Roundtable 3: Advanced therapies from the lab to industry. Science, investment and business aspects
Confirmed speakers and roundtable participants:
- Prof. David Raulet (University of California, Berkeley & founder Dragonfly Inc)
- Prof. Jordan Orange (Columbia University, NY)
- Prof. Eric Vivier (Aix-Marseille University & CSO Innate-Pharma)
- Prof. Todd Fehniger (Professor of Medicine, Washington University, St. Louis)
- Prof. Ulrike Kohl (Director of the Institute of Clinical Immunology, Leipzig, and Zelluna Immunotherapy)
- Prof. Luis Álvarez-Vallina, CNIO and Hospital 12 de octubre
- Prof. Katy Rezvani (Medical Director, Stem Cell Transplant and GMP Laboratories, MD Anderson Cancer Center, Houston, Texas)
- Dr. Sol Ruiz, Head of Biologics, Advanced Therapies, and Biotechnology, Spanish Medicines Agency (AEMPS)
- Dr. Charo Sánchez Pernauta, Biocruces Hospital, Bilbao
- Dr. Joaquim Vives, Barcelona Tissue Bank
- Dr. Marisol Quintero, CEO Highlight therapeutics
- Invivo partners
- Dr. Carolina Pola, CEO Stab therapeutics
Participants will also have the opportunity to present their ongoing research projects in the field of cancer immunotherapy, aligned with the mission of the IMMUNO-model COST Action: in addition to our invited talks, 8-10 abstracts will be selected for oral presentation and we will host a poster session.
For this Meeting, IMMUNO-Model COST Action will financially support some attendants with oral presentations. Selected presenters will be eligible to receive reimbursement for travel and accommodation costs, in line with COST Travel Reimbursement Rules, and subject t funds availability. All information can be found here: https://www.cost.eu/uploads/2025/04/Travel_Reimbursement_Rules_2025.pdf
For more information, please follow our social media channels and check your email for updates.
Registration will open in November 2025!